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Available online 13 April 2016Besides its vital role in immunity, the complement system also contributes to the shaping of the synaptic circuitry
of the brain. We recently described that soluble Complement Receptor 2 (sCR2) is part of the nerve injury re-
sponse in rodents. We here study CR2 in context of multiple sclerosis (MS) and explore the molecular effects
of CR2 on C3 activation.
Signiﬁcant increases in sCR2 levels were evident in cerebrospinal ﬂuid (CSF) from both patients with relapsing-
remitting MS (n = 33; 6.2 ng/mL) and secondary-progressive MS (n = 9; 7.0 ng/mL) as compared to controls
(n = 18; 4.1 ng/mL). Furthermore, CSF sCR2 levels correlated signiﬁcantly both with CSF C3 and C1q as well as
to a disease severitymeasure. In vitro, sCR2 inhibited the cleavage and down regulation of C3b to iC3b, suggesting
that it exerts a modulatory role in complement activation downstream of C3.
These results propose a novel function for CR2/sCR2 in human neuroinﬂammatory conditions.







The complement system, an important part of the innate immune
system, is activated in conditions of neuroinﬂammation where it con-
veys a range of effects comprising cell-lysis, chemotaxis, opsonization
and immune cell stimulation [1,2], but also contributes to tissue damage
[3–6]. All these functions result in clearance of debris and foreign mate-
rials. The complement system consists of a large number of compo-
nents, many of which derive from the liver, but where some are alsobrospinal ﬂuid; EDSS, Extended
le Sclerosis Severity Score;NFL,
RCA, regulator of complement
ry progressive MS.
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. This is an open access article underexpressed by immune/inﬂammatory cells such as macrophages, other
cells in various epithelium, endothelium, and intrinsic cells of the cen-
tral nervous system (CNS) such as neurons and glia [7,8]. Complement
activation is the result of a cascade of interacting processes, a structure
that enables ﬁne-tuning and adaptation, but also introduces multiple
levels where activation can be dysregulated [9].
A factor crucial for thedexterity of the complement system is cellular
responses mediated by several complement receptors present on a
range of cell types including macrophages [10], T- and B-lymphocytes
[11,12], microglia and astrocytes [13,14], which are either constitutively
or conditionally present in the neurological system. Many of the com-
plement receptors belong to a superprotein family (regulators of com-
plement activation, RCA) that contains the main regulators of
complement e.g. factor H and C4BP [9]. Also, many of the receptors
exist in both secreted andmembrane bound forms, for instance comple-
ment receptor 1 (CR1) and 2 (CR2) exist in soluble forms, e.g. sCR1 and
sCR2 (also known as sCD21) [15,16]. This has functional implications,
since soluble complement receptors can function as inhibitors instead
of activators [9], which are applied in complement directed therapies
[17].
The RCA proteins can act as regulators by inﬂuencing the
convertases by either decay acceleration of the convertases and/or by
acting as co-factors to factor I, which leads to downregulation ofthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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C3b to iC3b and thereafter iC3b to C3d,g. C3b is the only fragment that
can trigger activation of C5 (and subsequent generation of the mem-
brane attack complex, C5b-9). iC3b works mainly as a ligand to CR3
and CR4, while C3d,g is a ligand to CR2.
In the CNS an increasing body of evidence suggests that certain parts
of the complement system play important roles for shaping synaptic
networks during normal development and ageing, as well as being im-
plicated in different disease processes. For example, transgenic mice
lacking either C1q or C3 display aberrant innervation of visual pathways
and levels of C1q are greatly increased in both the ageing mouse and
human brain and correlate to cognitive decline [18–20]. However, the
intricate interplay between different complement components and
their interacting partners both during physiological conditions and in
different disease states is far from clariﬁed in detail.
We previously found considerable strain-dependent differences in
the local expression of several complement components in the spinal
cord of nerve-injured rats, and identiﬁed distinct regulatory pathways
[21,22]. Recently, using the same standardized rat nerve injury model,
we also demonstrated strain-dependent differences in the local expres-
sion of several complement receptors in the spinal cord [23]. Interest-
ingly, the most conspicuous ﬁnding was that of large differences in
CR2 both regarding tissue mRNA expression and presence of soluble
protein in cerebrospinal ﬂuid (CSF). A possible functional role for CR2
was suggested by a reduced elimination of synaptic connections as a re-
sult of axonal injury in mice lacking functional protein. The aim of the
current study was to extend these observations to human
neuroinﬂammatory disease and further characterize the function of
CR2 at the molecular level.
2. Material and methods
2.1. Ethics, consent and permissions
The study was approved by the regional ethical committee in
Stockholm (ethical permit 2009/2107-31/2) and written informed con-
sent was obtained from all patients.
2.2. Patients and CSF CR2/C3 determinations
CSF samples were collected during routine visits to the neurology
clinic at Karolinska University Hospital. Samples were centrifuged im-
mediately after lumbar puncture at 440g for 10 min at room tempera-
ture to separate cells from the CSF supernatant. The supernatants
were subsequently batched and stored at −80 °C until use. Patients
were subdivided into relapsing-remitting MS (RRMS), secondary pro-
gressive MS (SPMS) and other neurological disease (OND) controls
lacking signs of inﬂammatory components on magnetic resonance im-
aging and established markers of immune activation in the CSF
(pleocytosis, oligoclonal bands, increased albumin quotient and/or in-
creased IgG index). The OND controls were; psychosis n= 6; functional
paresthesia n = 4; peripheral mononeuropathy n = 3; vertigo n = 1;
lumbago = 1; syringomyelia n = 1; epilepsy n = 1; fatigue n = 1.
For detailed patient characteristics see Table 1. All clinical examinationsTable 1
Demographics and clinical characteristics of the patient cohort.
Diagnose n Sex (% females) Mean age years (SD) Disease duration at s
OND 18 55.6 30.4 (7.9) NA
RRMS 33 72.7 36.6 (9.6) 5.4 (0–19)
SPMS 9 55.6 52.0 (10.1) 17.0 (4–25)
All MS 42 69.0 39.9 (11.5) 7.9 (0–25)
RRMS, relapsing-remittingMultiple Sclerosis; SPMS, secondary progressiveMS; OND, other non
MSSS, MS Severity Score.were performed by a board certiﬁed specialist in neurology, and all pa-
tients diagnosed with MS fulﬁlled the McDonald criteria [24]. An Ex-
panded Disability Status Scale (EDSS) score for degree of neurological
disability was determined at time of sampling by a certiﬁed rater. To-
gether with estimated disease duration the EDSS score was used to cal-
culate the MS Severity Score (MSSS), a measure of disease severity [25].
One patient in the RRMS group and three patients in the SPMS group re-
ceived disease modifying treatment with beta-interferon at time of
sampling. Therewere no signiﬁcant concomitant diseases, such as infec-
tions, in any of the subjects and corticosteroids had not been givenwith-
in three months of sampling.
Levels of sCR2 (sCD21) were determined in undiluted CSF using a
human ELISA kit (USCN Life, Wuhan, China, cat.nr E0750h), according
to the manufacturer's instructions. The detection limit of the assay
was 0.3 ng/mL. All samples were analyzed in duplicateswith a resulting
intra-assay variability of 10%.
Complement protein C3 levelswere determined in 1:100 dilutedCSF
using an in house sandwich ELISA as previously described [26,27]. In
brief, wells of microtitre plates were coated with rabbit anti-C3c
(A0062, Dako, Glostrup, Denmark) diluted 1:3000, recognizing C3,
C3b, iC3b, and C3c. Detection of the bound C3/C3-fragmentswas carried
out with biotinylated anti-C3c diluted 1:3200, followed by streptavidin-
HRP diluted 1:500 (Amersham, Little Chalfont, UK). The concentration
of C3, in each sample was determined using DeltaSoft (BioMetallics
Inc, Princeton NJ, USA) software. A positive control of pooled plasma
from ﬁve blood donorswas included, and a samplewith known concen-
trations of C3 was used as a standard. The inter-assay variability was
19%. Also the levels of neuroﬁlament-light (NFL) was determined
using a commercial ELISA kit (UMAN Diagnostics AB, Umeå, Sweden)
in undiluted CSF according to themanufacturer's instructions. The levels
of C3 and NFL for some of the patients have previously been reported
[27].
In order to avoid complement activation in vitro, 10mMEDTA (ﬁnal
concentration) was added to the CSF samples immediately after
thawing. For C1q determination microtitre plates were coated with
anti-C1q (A0136, Dako) diluted 1/3000. Detection of bound C1q was
performed using biotinylated anti-C1q, followed by streptavidin-
horseradish peroxidase (HRP) diluted 1/500 (Amersham). The inter-
assay variability was 7.1%.
2.3. Co-factor activity of CR2
C3b, factor I (fI), and factor H (fH) were prepared from human plas-
ma as previously described [28] and recombinant soluble CR2 was pur-
chased from R & D Systems (Minneapolis, MD). The potential ability of
CR2 to act as a co-factor for fImediated cleavage of C3bwas investigated
by incubating C3b (10 μg), fI (0.6 μg) together with CR2 in various con-
centrations (2.8–8.4 μg), for 60 min at 37 °C. FH (0.5 to 2 μg) is well-
established to mediate C3 cleavage [29] and served as positive control.
In additional experiments, iC3b (available for CR2 to bind to) was gen-
erated by incubating C3b with fI and fH in the presence of CR2 (1.4–
5.6 μg). After incubation all samples were subjected to SDS-PAGE
under reducing conditions and the gels were stained using Coomassie.
In addition, the generated C3 fragments were visualized by westernampling average years (range) EDSS median (range) MSSS median (range)
NA NA
2 (0–4.5) 4.9 (0.7–7.9)
5.5 (4–6.5) 2.7 (1.0–5.5)
2.5 (0–6.5) 3.3 (0.7–7.9)
-inﬂammatory neurological/psychiatric conditions; EDSS, ExtendedDisability Status Scale;
Fig. 1. Levels of soluble CR2 (sCR2) are increased in cerebrospinal ﬂuid from patients with Multiple Sclerosis and correlate with levels of C3 and C1q. Levels of soluble CR2 (sCR2) were
quantiﬁed in the CSF in a well characterized cohort of MS patients and a control group consisting of patients with non-inﬂammatory neurological/psychiatric diseases (OND). This
demonstrated signiﬁcantly increased levels of sCR2 in patients compared to controls (All MS: 6.40 ± 0.33, OND: 4.12 ± 0.37) (A). The levels of C1q were also increased in the MS
group (329.4 ± 11.4 μg/L) compared to controls (251.6 ± 9.8 μg/L) (B). CSF levels of sCR2 correlated with C3, suggesting that increased it may serve a counter-regulatory role in
situations where C3 activation is increased (C). The levels of sCR2 also correlated with C1q (D).
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tion was performed using streptavidin-HRP (GE-Healthcare, Bucking-
hamshire, UK) and detection by chemiluminescence with ECL Plus
Western Blotting Detection system (GE-Healthcare).
2.4. Statistical analysis
The software program R 2.6.0 was used to carry out statistical anal-
yses and create all graphs. One-way ANOVA calculated with GraphPad
Prism 5.0 (San Diego, CA) were carried out on protein data, results are
represented as mean ± SEM. Correlations between protein levels in
clinical samples, were calculated using Pearson's algorithm assuming
equal distribution, and visualized graphically using linear regression
plots, also in GraphPad Prism 5.0. p b 0.05 was considered statistically
signiﬁcant.
3. Results
3.1. CR2 exists in a soluble form in the intrathecal compartment
In order to replicate our previous ﬁnding from rats, we determined
levels of sCR2 in CSF from 33 RRMS patients, 9 SPMS patients and a con-
trol group consisting of 18 individuals without signs of intrathecal in-
ﬂammation (for patient characteristics see Table 1). The mean level of
sCR2 in OND controls was 4.1 ng/mL compared to 6.2 ng/mL in RRMS
and 7.0 ng/mL in SPMS patients (Fig. 1A, Table 2). The levels of C3
were 1853 ± 171 μg/L in the OND group and signiﬁcantly higher
(2498 ± 139 μg/L) in the MS group (Table 2), these data have in part
been published previously [27]. The levels of C1q were also higher in
the MS patients compared to the controls; 251.6 ± 9.8 μg/L in theOND group and 329.4 ± 11.4 μg/L in the MS group, with the highest
levels seen in SPMS patients (ﬁg. 1B, Table 2).
3.2. CR2 correlates with levels of C3 as well as to Multiple Sclerosis Severity
Score
Furthermore, we found that sCR2 levels displayed a strong positive
correlation to both C3 (Fig. 1C) and C1q (Fig. 1D). sCR2 also correlated
with albumin quotient (Fig. 2A, Table 2). In contrast, therewas no signif-
icant correlation between sCR2 and NFL (Fig. 2B, Table 2), a commonly
used surrogate marker of ongoing neuroaxonal degeneration in MS
[30]. When correlating the sCR2 levels with the clinical parameters at
time of sampling we saw a signiﬁcant correlation between Multiple
Sclerosis Severity Score (MSSS), a measure of disease severity, and
sCR2 (Fig. 3A, Table 1). The pattern was similar, but not signiﬁcant for
sCR2 and Extended Disability Status Scale (EDSS), a measure of neuro-
logical disability, (Fig. 3B, Table 1). However, when stratifying into the
group with higher EDSS (4 and above) the levels of sCR2 were signiﬁ-
cantly higher in the group with higher EDSS (Fig. 3C).
3.3. CR2 inhibits generation of iC3b by interfering with factor H
C3b is cleaved by the plasma protease fI in three positions. The ﬁrst
two cleavages give rise to iC3b and a third subsequent cleavage to
C3d,g [31]. The cleavage process occurs only in the presence of a co-
factor binding to C3b and thereby causing a conformational change,
which makes the cleavage sites accessible for fI. The co-factor activity
can be measured by the relative reduction in the band corresponding
to the 101 kDa α-chain of C3b and the corresponding increase of the
cleaved product, the 67 kDa band of iC3b. The third cleavagewill reduce
Table 2
Biochemical analysis of cerebrospinal ﬂuid from patients and controls.
sCR2 average (SEM) C3 average (SEM) C1q average (SEM) NFL average (SEM) Albumin quotient (SEM)
Diagnosis n ng/mL μg/mL μg/mL μg/mL
OND 18 4.12 (0.37) 1853 (170.8) 251.6 (9.8) 233.2 (26.85) 4.53 (0.51)
RRMS 33 6.24 (0.36) 2320 (142.9) 318.7 (13.2) 2019 (334.0) 4.84 (0.36)
SPMS 9 6.96 (0.81) 3148 (313.1) 368.5 (16.9) 1378 (457.6) 6.50 (1.22)
All MS 42 6.40 (0.33) 2498 (139.4) 329.4 (11.4) 1882 (280.8) 5.18 (0.39)
RRMS, relapsing-remittingMultiple Sclerosis; SPMS, secondary progressiveMS; OND, other non-inﬂammatory neurological/psychiatric conditions. The normal reference value for the CSF
albumin quotient is b7.
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C3d,g band.
To assess the ability of CR2 to modify cleavage of the α-chain of C3b
to iC3b, C3bwas ﬁrst incubated with 0.6 μg fI and increasing concentra-
tions of CR2, however, with no discernible effect on the C3b/iC3b rela-
tion on SDS-PAGE (Fig. 4A, lanes 2–4). In contrast, the positive control
using C3b incubatedwith fI and increasing concentrations of fH resulted
in almost total disappearance of the 101 kDa band and appearance of a
strong 67 kDa iC3b band, as well as smaller break-down products
(Fig. 4A, lanes 6–8).
As a subsequent step we studied the effect of CR2 in the presence of
both fI and fH. Interestingly, increasing concentrations of CR2 now re-
sulted in decreased degradation of C3b, as well as less generation of
iC3b and the 40 kDa band likely representing C3d,g, suggesting that
CR2 blocks the interaction between C3b and factor H (Fig. 4B, lanes 3–
5, Fig. 4C, lanes 3–5).
4. Discussion
We here demonstrate that sCR2 is detectable in human CSF and that
levels are upregulated in patients with MS compared to non-
inﬂammatory controls. At the molecular levels we ﬁnd evidence that
CR2 regulates the function of C3. Theseﬁndings extend our previous ob-
servations of a strong genetic inﬂuence on the local expression of CR2 in
the spinal cord of rats subjected to a standardized nerve injury, which
also was reﬂected in the levels of sCR2 in CSF [23]. Furthermore, a func-
tional role for CR2 was suggested by the observation of an increased
elimination of synaptic elements in the injured area of transgenic mice
lacking functional CR1/2, which are transcribed from the same gene in
mice but not rats or humans, compared to wild type [23].
The notion that the complement system may exert important regu-
latory functions on the shaping of neuronal networks is of recent date.
Thus, in 2007 Stevens and co-workers reported that mice lacking C1q
or C3 displayed defective developmental elimination of synapticFig. 2. Correlations between sCR2, the albumin quotient and NFL in MS patients. At the time of
often used to illustrate blood-brain barrier integrity however not with NFL (B), a commonly usconnections in the visual pathway [18]. Subsequent studies have re-
vealed that a dynamic interplay between neurons and microglia medi-
ated by immune factors such as C1q and C3 play an important role for
the shaping and homeostatic plasticity of the brain synaptic circuitry
[19]. Thus, microglia have been implicated in the removal of synapses
occurring after CNS injury, where complement is known to increase
their phagocytic properties through receptors such as CR3 (CD11b/
CD18), the expression of which characterizesmicroglia with phagocytic
potential [19,32]. The relevance of C3-CR3 communication is supported
by the ﬁnding that mice deﬁcient for CR3 display reduced loss of synap-
ses during development of the visual system, i.e. a phenotype that is
similar to that of mice lacking C3 [18,19].
Complement mediated synaptic plasticity is not limited to physio-
logical functions during normal development, but may also constitute
an important biological substrate for chronic neurodegenerative dis-
eases, since failure to regulate the system may lead to excessive loss of
synaptic connectivity, in turn representing an early disease related phe-
nomenon in models of neuroinﬂammation and neurodegeneration [33,
34]. Signs of complement activation are readily evident in neurodegen-
erative diseases such as Alzheimer's (AD) and Parkinson's diseases, but
also in MS [5,35]. An important question is if dysregulation of the com-
plement systemmerely reﬂects downstream effects of an inherent neu-
rodegenerative process. However, the fact that genetic variability in
both Clusterin and CR1 genes are associated to risk of late-onset AD
[36,37] suggests that this is not the case, but rather that excessive acti-
vation may indeed trigger or exaggerate neurodegenerative processes.
CR2 has mostly been studied in context of B cell and follicular den-
dritic cell immunology, where CR2 forms a co-receptor complex togeth-
er with CD19 and CD81, and CR2 binds opsonized C3d,g and antigen-
bound IgM that in turn results in a more efﬁcient humoral immune re-
sponse [38]. In contrast, any possible function of CR2 in the CNS has re-
ceived little attention, even if expression of CR2 by activated astrocytes
has been reported [14]. More recently CR2 has also been shown to reg-
ulate neurogenesis in the mouse [39]. In another recent study CR1/CR2sampling, the levels of soluble CR2 (sCR2) correlated well with the albumin quotient (A),
ed surrogate marker of ongoing neuroaxonal degeneration in MS.
Fig. 3. Correlations between sCR2 and clinical parameters in MS patients. The levels of soluble CR2 (sCR2) at the time of sampling were correlated with the two most frequently used
clinical scoring scales in MS; Multiple Sclerosis Severity Score (MSSS) and Extended Disability Status Scale (EDSS). sCR2 levels correlated with MSSS (A) but not with EDSS (B).
However, when stratiﬁed into high and low EDSS, the high EDSS group had increased sCR2 levels (C). n = 18 OND; 33 RRMS; 9 SPMS patients respectively. The results are
represented as mean ± SEM.
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imental traumatic brain injury model compared to wild-type mice [40].
The authors also reported that the deposition of C3 in the brain tissue
was reduced in animals lacking CR1/CR2. The fact that both receptors
are transcribed from the same gene inmice, however, makes extrapola-
tions to human conditions uncertain. Still, the ﬁndings provide some
support for a functional role for CR2 in the response to nerve injury.
The existence mainly of a soluble form of CR2 in the CNS could ex-
plain why immunohistochemical detection has proven difﬁcult [39]. In
fact, while tissue stainings were weak in the rat, sCR2 was readily de-
tectable in CSF and levels increased following a standardized nerve inju-
ry leading to localized inﬂammatory activation in the spinal cord, but
with very little inﬂux of blood derived immune cells [23]. Possibly in-
creased sCR2 may not only be regulated at the transcriptional levels,
but can also be the result of increased shedding of the CR2 ectodomain
due to oxidative stress [41,42]. We here demonstrate the presence of
sCR2 also in human CSF and that levels increase in conditions of inﬂam-
mation. Interestingly, decreased serum sCR2 levels have been reported
in MS [43], alike multiple other autoimmune diseases [44–46]. If this
is due to reduced production or increased consumption during autoim-
mune inﬂammation is not known.
We also found a signiﬁcant correlation between CSF C1q/C3 and
sCR2 levels. The role of complement in MS has received increasing at-
tention, with a suggested role in the neurodegenerative processesFig. 4.CR2doesnot contribute cleavage of C3b but inhibits generation of iC3b. A: To assess the fu
was incubated together with either 0.6 μg factor I (fI) only (lane 1) or with 0.6 μg factor I and in
discernible effect of CR2 on C3b cleavage as judged from the intensity of the 101 kDa band. As
factor H (0.5/1/2 μg) (lanes 6–8), which demonstrated cleavage of C3b to iC3bwith disappearan
break-down products. The band at 75 kDa is the C3b beta chain which is unaffected in all condit
was incubated with; 0.6 μg fI (lane 1); 0.6 μg fI together with 0.5 μg fH (lane 2); or 0.6 μg fI toge
demonstrated decreased degradation of the 101 kDa C3b band, aswell as decreased generation
is also weaker with increasing concentrations of CR2, which likely represents C3dg. C: The exp
products using the same conditions as in (B), i.e. 10 μg C3b was incubated with; 0.6 μg fI (la
increasing concentrations of CR2 (1.4/2.8/5.6 μg) (lanes 3–5). The results again showed less b
less C3dg with increasing CR2. M =molecular weight marker.[47]. For example, certain types of MS lesions are characterized by
prominent complement activation [48], and elevated complement
levels have been demonstrated in serum of MS patients [35,49], as
well as in the CSF in protein proﬁling studies [4,50]. In addition, we pre-
viously reported that C3 levels in CSF of MS patients correlate with de-
gree of neurological disability as well as CSF levels of NFL [27].
C3 is a large and complexmolecule, withmultiple active breakdown
products. Therefore, elevated sCR2 could reﬂect an intrinsic regulatory
mechanism in the CNS, where up regulation and/or increased shedding
of CR2 serves to modulate increased C3 activity. In fact, we here found
molecular evidence supporting this notion, since CR2 in vitro inhibited
cleavage of C3b into iC3b. This is likely of importance, since C3b (in con-
trast to iC3b) is able to amplify the alternative pathway ampliﬁcation
loop leading to deposition of C3b at sites of inﬂammation and to trigger
C5 activation and C5a/C5b-9 associated damage and inﬂammation,
i.e., anaphylaxis and cell lysis. Reduced generation of iC3b will impair
the clearance of debris from the inﬂammatory site, since this fragment
is the primary ligand for CR3 (CD11b/CD18) [51], whereas C3b is not
bound by CR3 [52] but instead by CR1 [53]. Thus, it may be speculated
that increased levels of sCR2 in context of nerve injury limit iC3b gener-
ation, in turn reducing iC3b-CR3 mediated microglial synaptic removal
[19]. This hypothesis is interesting in the light of previous postulations
of the neurodegenerative disease progression, where loss of synaptic
connectivity constitutes an early process [33,34].nction of CR2 and its ability to cleaveC3b alpha chain (101 kDa) to iC3b (67 kDa), 10 μg C3b
creasing concentrations of CR2 (2.8/5.6/8.4 μg) (lanes 2–4) using SDS-PAGE. There was no
a positive control C3b was incubated with 0.6 μg factor I with increasing concentrations of
ce of the 101 kDa band and appearance of a new band at around 67 kDa, aswell as smaller
ions. B: To assess the function of CR2 in the presence of both fI and factor H (fH) 10 μg C3b
ther with 0.5 μg fH and increasing concentrations of CR2 (1.4/2.8/5.6 μg) (lanes 3–5). This
of iC3b, suggesting that CR2 blocks the interaction betweenC3b and fH. The band at 40 kDa
eriment was repeated using western blot and with an antibody recognizing C3b cleavage
ne 1); 0.6 μg fI together with 0.5 μg fH (lane 2); or 0.6 μg fI together with 0.5 μg fH and
reakdown of the alpha chain C3b, with increasing concentrations of CR2. Again, there is
94 R.P.F. Lindblom et al. / Clinical Immunology 166–167 (2016) 89–955. Conclusions
We here ﬁnd that MS patients display elevated CSF levels of sCR2,
which correlate both with C3 and C1q, but less well with biomarkers
of nerve injury. We also provide novel evidence that sCR2 impairs the
cleavage of C3b into active metabolites in vitro suggesting that it has a
modulatory function in situations of complement activation. Further
work is needed to explore if CR2/sCR2 treatment is feasible and beneﬁ-
cial in conditions characterized by loss of nerve terminals and dysregu-
lated expression of complement, for example chronic
neurodegenerative disorders.
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